ramucirumab,pembrolizumab
eli lilly,merck
['nsclc', 'platinum', 'sclc', 'lcsm,(-blcsm)']
at #esmo22 is presenting exploratory analysis from s1800a, a study investigating os w/ a vegfr2 inhibitor + a pd1 inhibitor in pts w/ advanced #nsclc following progression on prior ici &amp; platinum chemotherapy. #lcsm view presentation: 
Dedicated to communicating the latest science & innovation from Loxo@Lilly. Tweets intended for US oncology HCPs. See our community guidelines: https://t.co/1q8vAe63mK